PMID- 11900415
OWN - NLM
STAT- MEDLINE
DCOM- 20020404
LR  - 20131121
IS  - 1532-0820 (Print)
IS  - 1532-0820 (Linking)
VI  - 52
IP  - 1
DP  - 2002 Feb
TI  - Early effects of tribromoethanol, ketamine/xylazine, pentobarbitol, and 
      isoflurane anesthesia on hepatic and lymphoid tissue in ICR mice.
PG  - 63-7
AB  - We investigated the effects of various anesthetic agents on hepatic and splenic 
      injury in mice. Three and six hours after intraperitoneal injection of TBE, 
      intramuscular injection of ketamine/xylazine combination (K/X), intraperitoneal 
      injection of pentobarbital (PB), and inhalation of isoflurane (IF), or 
      intraperitoneal and intramuscular injection of control saline, mice were 
      exsanguinated and serum was obtained for measurement of hepatic aspartate 
      transaminase (AST), alanine transaminase (ALT) and gamma-glutamyltransferase 
      (GGT). The spleen and liver also were obtained, and sections were examined by use 
      of routine light microscopy for pathologic changes and for apoptosis, as 
      determined by use of the in situ terminal deoxynucleotidyl transferase-mediated 
      dUPT nick-end-labeling (TUNEL) histochemical analysis. Three hours after TBE or 
      K/X administration, AST activity increased three- to fourfold above that in 
      untreated and saline-injected control animals, and remained high at six hours. 
      Administration of PB did not effect AST activity at three hours, but there was a 
      significant increase at six hours. Activity of ALT was non-significantly 
      increased three hours after TBE and K/X, but not PB administration. 
      Administration of IF had no effect on hepatic enzyme activities, and GGT was not 
      increased after administration of any of the agents. Markedly increased apoptosis 
      was observed in splenic follicles and in hepatic Kupffer and endothelial cells at 
      three hours after TBE and K/X administration, but apoptosis decreased to control 
      levels by six hours. Increased apoptosis was not observed after IF 
      administration. Administration of TBE and K/X causes injury to lymphocytes and to 
      hepatic Kupffer and endothelial cells within three hours, and PB administration 
      induces changes within six hours. Thus, use of these anesthetic agents should be 
      avoided when experiments are being designed to test short-term effects of an 
      experimental intervention on the spleen and possibly on all lymphoid tissues. In 
      addition, they also should be avoided in experiments testing effects on hepatic 
      tissue.
FAU - Thompson, John S
AU  - Thompson JS
AD  - Department of Internal Medicine and Sanders-Brown Center on Aging, University of 
      Kentucky, Lexington 40536-0298, USA.
FAU - Brown, Stephen A
AU  - Brown SA
FAU - Khurdayan, Valarie
AU  - Khurdayan V
FAU - Zeynalzadedan, Amenah
AU  - Zeynalzadedan A
FAU - Sullivan, Patrick G
AU  - Sullivan PG
FAU - Scheff, Stephen W
AU  - Scheff SW
LA  - eng
GR  - NS 39828/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Comp Med
JT  - Comparative medicine
JID - 100900466
RN  - 0 (Anesthetics)
RN  - 0 (Drug Combinations)
RN  - 149JI83A44 (tribromoethanol)
RN  - 2KFG9TP5V8 (Xylazine)
RN  - 3K9958V90M (Ethanol)
RN  - 690G0D6V8H (Ketamine)
RN  - CYS9AKD70P (Isoflurane)
RN  - EC 2.3.2.2 (gamma-Glutamyltransferase)
RN  - EC 2.6.1.1 (Aspartate Aminotransferases)
RN  - EC 2.6.1.2 (Alanine Transaminase)
RN  - I4744080IR (Pentobarbital)
SB  - IM
MH  - Alanine Transaminase/metabolism
MH  - Anesthetics/*adverse effects
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Aspartate Aminotransferases/metabolism
MH  - Drug Combinations
MH  - Ethanol/adverse effects/*analogs & derivatives
MH  - In Situ Nick-End Labeling
MH  - Isoflurane/adverse effects
MH  - Ketamine/adverse effects
MH  - Liver/*drug effects/enzymology/pathology
MH  - Male
MH  - Mice
MH  - Mice, Inbred ICR
MH  - Pentobarbital/adverse effects
MH  - Spleen/*drug effects/pathology
MH  - Xylazine/adverse effects
MH  - gamma-Glutamyltransferase/metabolism
EDAT- 2002/03/20 10:00
MHDA- 2002/04/18 10:01
CRDT- 2002/03/20 10:00
PHST- 2002/03/20 10:00 [pubmed]
PHST- 2002/04/18 10:01 [medline]
PHST- 2002/03/20 10:00 [entrez]
PST - ppublish
SO  - Comp Med. 2002 Feb;52(1):63-7.